Comparative Pharmacology
Head-to-head clinical analysis: GEOPEN versus KLEBCIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GEOPEN versus KLEBCIL.
GEOPEN vs KLEBCIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Carbenicillin is a bactericidal penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has activity against Gram-negative and some Gram-positive bacteria.
Klebcillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
2 g intravenously every 6 hours for susceptible infections.
KLEBCIL (ceftazidime-avibactam) 2.5 g (ceftazidime 2 g + avibactam 0.5 g) IV every 8 hours infused over 2 hours.
None Documented
None Documented
Terminal half-life 4-6 hours in normal renal function; prolonged to 10-20 hours in moderate renal impairment (CrCl 10-50 mL/min) and up to 30-50 hours in severe impairment (CrCl <10 mL/min).
2-3 hours (prolonged to 30-60 hours in severe renal impairment; adjust dosing)
Renal: 80-90% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: <2%.
Primarily renal (70-80% unchanged); minor biliary/fecal (15-20%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic